Global Erectile Dysfunction Market 2016-2020
About Erectile Dysfunction
The loss of erection can be attributed to various factors such as high blood pressure, aging, diabetes mellitus, smoking, alcoholism, depression, nerve or spinal cord damage, and low testosterone levels. The condition can be treated with a broad range of drugs and implants available in the market.
Technavio’s analysts forecast the global erectile dysfunction treatment market to witness a slow grow in market size of USD 4.08 billion during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global erectile dysfunction treatment market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of different types of penile implants, ED creams, and drugs, including branded and generic drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Erectile Dysfunction Treatment Market 2016-2020
Technavio recognizes the following companies as the key players in the global erectile dysfunction treatment market: Bayer, Boston Scientific, Coloplast, Eli Lilly, and Pfizer.
Other Prominent Vendors in the market are: Apricus Biosciences, Cristalia Produtos Quimicos Farmaceuticos, Dong-A Socio, Endo Pharmaceuticals, Futura Medical, Meda Pharmaceuticals, Promedon, SK Chemical, Teva Pharmaceuticals, Vivus, and Zephyr Surgical Implants (ZSI).
Commenting on the report, an analyst from Technavio’s team said: “One of the key drivers for market growth will be migration of manufacturing and sales facilities to APAC. In the recent years many manufacturers of ED products have either established or expanded their current manufacturing and sales network in APAC. This is primarily to capitalize on the high number of ED cases, economy of production offered, and to find easy access to domestic markets at a cheaper logistical cost. The region provides an attractive proposition of low cost of land and material, easily availability of labour, and access to a larger population that will contribute to the growth of the market in the future.”
According to the report, demand from older adult male population will be a key driver for market growth. An increase in sophisticated treatment options and improved standards of healthcare facilities have resulted in an increase in the life expectancy rates leading to a growing older adult population worldwide. With age, the physical, and hormonal changes in the body can cause a decrease in libido, which is a side effect of ED that can occur at any age. ED is more common among older men; seen mostly in men over 40 years of age. The increase in chances of older men getting affected by ED is associated with an unhealthy lifestyle and an increase in stress related activities over the years leading to a decrease in level of libido.
Further, the report states that the main challenge for the market is the patent expiration of major drugs, which will lead to the introduction of a broad range of generic drugs of similar chemical composition for the treatment of ED. These drugs will be available at a much cheaper cost, which can be attributed to limited legal procedures as well as less production expenses related to these generic drugs.
Bayer, Boston Scientific, Coloplast, Eli Lilly, Pfizer, Apricus Biosciences, Cristalia Produtos Quimicos Farmaceuticos, Dong-A Socio, Endo Pharmaceuticals, Futura Medical, Meda Pharmaceuticals, Promedon, SK Chemical, Teva Pharmaceuticals, Vivus, and Zephyr Surgical Implants (ZSI).